Quantcast
Last updated on April 21, 2014 at 7:52 EDT

Latest Paricalcitol Stories

2013-05-21 12:27:32

ISTANBUL, May 21, 2013 /PRNewswire/ -- The congress of the ERA-EDTA (European Renal Association - European Dialysis and Transplant Association) is the biggest congress in Europe on nephrology and renal replacement therapy. Nearly 10,000 participants are in Istanbul to share their knowledge and discuss the latest research findings. New pioneering studies have been presented: / (1) Gupta, A et al. "SOLUBLE FERRIC PYROPHOSPHATE (SFP) ADMINISTERED VIA HEMODIALYSATE REDUCES...

2012-06-01 02:24:41

MARKHAM, ON, June 1, 2012 /PRNewswire/ - Cytochroma today announced that it has regained the rights to all indications in the United States (US) and in Asian territories to lunacalcipol (previously known as CTA018) through the termination of a license agreement between Cytochroma and Mitsubishi Tanabe Pharma Corporation ("MTPC").  MTPC and Cytochroma mutually decided to suspend further development of lunacalcipol injection based on changing US market dynamics. "We are...

2012-05-11 02:23:45

MARKHAM, ON, May 11, 2012 /PRNewswire/ - Cytochroma today announced positive clinical trial results for its lead product, CTAP101 Capsules.  In a recently completed Phase 2b trial, CTAP101 Capsules effectively and safely lowered elevated plasma intact parathyroid hormone (iPTH) in patients with Stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency.  These findings, as well as two other presentations on CTAP101 Capsules, are being featured at the National...

2012-04-03 02:27:11

MARKHAM, ON, April 3, 2012 /PRNewswire/ - Cytochroma today announced that the United States Patent and Trademark Office (USPTO) issued a Notice of Allowance for US Patent Application # 13/244,945.  This patent application, entitled "Method for Treating Secondary Hyperparathyroidism in CKD", covers the anticipated method of use of the Company's lead product, CTAP101 Capsules, which is in phase 3 development for treating patients with Stage 3 or 4 chronic kidney disease (CKD),...

2012-02-15 10:41:44

Patients with chronic kidney disease who received the vitamin D compound paricalcitol for up to 48 weeks did not show improvement on measures of cardiac structure, function, or left ventricular mass, compared to patients who received placebo, according to a study in the February 15 issue of JAMA. "Although primarily recommended for improving bone health, treatment with vitamin D recently has been suggested for other conditions, including cardiovascular disease (CVD)," according to...

2012-02-15 10:36:10

JAMA study finds no effect on cardiac structure or function, hints at possible reduction in heart failure Almost a year's treatment with a vitamin D compound did not alleviate key structural and functional cardiovascular abnormalities in patients with kidney disease and cardiac enlargement. In a paper in the February 15 Journal of the American Medical Association, an international research team reports that daily doses of a vitamin D compound did not reduce enlargement or improve impaired...

2011-06-28 08:51:00

PRAGUE, June 28, 2011 /PRNewswire/ -- The 48th ERA-EDTA congress was the setting for a wide range of new clinical data. The "Late-Breaking Clinical Trials" were met with particular interest, one of them being the IMPACT SHPT study (Evaluation of the Effectiveness of Paricalcitol Versus Cinacalcet With Low-Dose Vitamin D). In the oral presentation on 25 June the principal investigator of this study, Prof. Markus Ketteler (Coburg, Germany), summarized the final data, whereas the...

2011-06-25 09:30:00

PRAGUE, June 25, 2011 /PRNewswire/ -- The SHARP-study has shown that lowering LDL cholesterol with ezetimibe/simvastatinleads to a significant reduction in major atherosclerotic events among CKD-patients. Whether it also has a favourable effect on renal disease progression was another of the issues addressed by the SHARP study [abstract no. 2509]. In the ezetimibe/simvastatin group, fewer patients reached the end point "end stage renal disease", but the difference was not...

2011-02-17 07:00:00

MARKHAM, ON, Feb. 17 /PRNewswire/ - Cytochroma today announced the initiation of a repeat-dose safety and efficacy study of CTAP101 Capsules in patients with vitamin D insufficiency, secondary hyperparathyroidism (SHPT) and stage 3 chronic kidney disease (CKD). "Vitamin D insufficiency in CKD patients is a significant problem associated with increased mortality and morbidity and for which no approved treatment is available," stated Joel Z. Melnick, M.D., Cytochroma's Vice President,...

2010-11-29 11:40:00

EXTON, Pa., Nov. 29, 2010 /PRNewswire/ -- BioTrends Research Group, Inc. released ChartTrends®: Bone and Mineral Metabolism in Chronic Kidney Disease Non-Dialysis (CKD-ND), an annual syndicated publication based on patient and laboratory data collected from over 1,000 U.S. CKD-ND patient charts. This report both quantifies and characterizes CKD stage 3, 4 and 5 patients under the care of a nephrologist, identifying referral patterns, physician co-management, frequency of...